New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
08:42 EDTCLDNCelladon's Mydicar candidate granted breakthrough therapy designation by FDA
Celladon's lead product candidate, Mydicar, has been granted breakthrough therapy designation by the FDA for reducing hospitalizations for heart failure in NYHA class III or IV chronic heart failure patients who are NAb negative. This designation is intended to expedite the development and review of drugs for serious or life-threatening conditions. Celladon is currently evaluating Mydicar in the Phase 2b CUPID 2 trial to determine its efficacy in reducing the frequency of and/or delaying heart failure-related hospitalizations. The company expects to report results in April 2015.
News For CLDN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2015
16:38 EDTCLDNCelladon modifies executive severance terms amid continued sale, merger search
In a regulatory filing, Celladon reported that on September 25, its board of directors approved modifications to the severance arrangements of several executive officers, including CEO Paul Cleveland and CFO Andrew Jackson. Celladon remarked, "As the company continues with the process of seeking a merger, sale or other disposition of the company, the board of directors has deemed it advisable, and in the best interests of the company's stockholders, to incentivize the executive officers identified above to continue their employment with the company for an additional period of time."

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use